大脑透性免疫蛋白质向性宏环EPEPTIDEEPOXYKETONES用于阿尔茨海默病的疾病
Ji Eun Park1, Chhabi Lal Chaudhary2, Deepak Bhattarai2
1Center for Translational Science, Florida International University, 11350 SW Village Pkwy, Port St. Lucie, Florida 34987, United States.
Journal of medicinal chemistry
|April 18, 2024
概括
针对免疫蛋白酶体 (iP) 的新型宏环环氧基对阿尔茨海默病 (AD) 具有前景. 化合物5在小鼠中表现出良好的血脑屏障透和目标接触,表明其作为AD治疗候选者的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 免疫蛋白酶体 (iP) 抑制可以改善阿尔茨海默病 (AD) 鼠标模型中的认知缺陷.
- 宏环环氧基为IP向提供了比线性对应物更好的代谢稳定性.
研究的目的:
- 识别和描述新型宏环环氧基作为潜在的AD治疗方法.
- 在体内评估化合物的脑透和目标接触.
主要方法:
- 对Caco2细胞透性和微体稳定性的宏环环氧基的合成和评估.
- 艾姆斯试验和BV2细胞强度测试用于评估化合物的安全性和有效性.
- 在BALB/c小鼠中静脉和口服给药化合物5以评估大脑IP抑制.
主要成果:
- 根据透性和稳定性确定了四种优化的宏环性IP抑制剂.
- 在艾姆斯和功效测试后,化合物5被选为主要候选药物.
- 在服用第5种化合物后,在小鼠大脑中观察到显著的IP抑制,这表明血脑屏障透.
结论:
- 化合物5是阿尔茨海默病治疗的有希望的药物头.
- 已识别的宏环环氧基具有进一步研究的潜力,作为针对免疫蛋白质组的AD疗法.
相关概念视频
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468